LiFe-saving tissue therapeutics

Making cell therapies implantable

Cellbricks develops implantable tissue therapeutics to help patients live longer, healthier lives, leveraging its proprietary biofabrication platform and 10 years of tissue engineering expertise.

The Problem We Solve

Current injectable cell therapies do not achieve sustainable efficacy due to a lack of engraftment in the patient.

Solution: Implantable tissue therapeutics

Sustainable effect at the target tissue
Vascularised
Immune compatible

Tissue therapeutics represent a new category of regenerative medicine by making cell therapies implantable, resulting in stable engraftment and effective treatment.

Tissue ThERAPEUTIC PROGRAMS

Cellbricks develops biofabricated tissue therapeutics that are biologically functional, immune-compatible, and optimized for surgical implantation.

Cellbricks Figure - Therapeutic Programs

We have two therapeutic programs with the potential to redefine treatment for diseases that are currently incurable.

Technology

Cellbricks combines therapeutic cells with tailor-made biomaterials via its proprietary biofabrication platform centered around light-based bioprinting to create implantable tissue therapeutics.

Therapeutic Cells

Multiple types

biomaterials

Liquid extracellular matrix (including recombinant production)

3D-Bioprinter

The design and reproducible imprinting of cells using light, at organ sized volumes, with vasculature, within minutes.

tissue

Immune compatible vascularized organ tissue at industrial scale.

Advantages of Cellbricks' light-based multi-material 3D-bioprinting technology:

Very cell-friendly

Multiple cell types

High speed and resolution

Large volumES

Cellbricks reconciles the most important requirements for industrial production of vascularized, functional, complex and implantable human tissue.

Team and Career

Our team brings together scientific and operational expertise with the mission to bring live-saving tissue therapeutics into the clinic enabling patients to live longer and healthier lives.

Leadership

Alexander Leutner

Chief Executive Officer

Founded, scaled & exited previous deep-tech start-up Apodius to Hexagon.

12 years building and leading teams in start-up and corporate settings, deal-making with key accounts and top-level management (incl. M&A process), MSc mechanical engineering.

DR. SIMON MACKENZIE

Chief Operating Officer

Former CEO at RegenHU; CBO at Axol Bioscience; Director at Kyorin Pharmaceutical Co.

25 years building and leading biotech and pharma therapeutics teams across US, EU, Asia; Expertise in iPSCs, bioprinting, pharma partnering; PhD biochemistry with 26 publications and patent.

Joachim von Arnim

Chief Strategy Officer

Founded, scaled and led a deep-tech focused family office.

8 years investing in tech companies; Legal qualifications and IP expertise; MSc mechanical engineering with additional studies in business and law.

Alexander Thomas

Head of Therapeutic program

Cellbricks founder;
PhD on bioprinted vasculature

10 years experience 3D-bioprinting & tissue engineering; Expertise in vasculature and biomaterials; 10 publications.

Dr. Alicia Ruppelt

Head of Therapeutic program

Former R&D liver engineer at LifeTec Group; Researcher at Merck

6 years experience 3D-bioprinting & tissue engineering. Scientific and managerial industry expertise; PhD biotechnology,
4 publications.

Dr. Tobias LAM

Head of Technology

Cellbricks founder;
Created bioprinting technology

10 years experience 3D-bioprinting &
3D-bioprinter development; PhD biotechnology, 12 publications.

We are an interdisciplinary team of entrepreneurs, engineers, chemists and biologists driven by excellence and proactive spirit. With every new team member, we add more passion and expertise to our mission. Check our open roles and see where you fit.

-> Unfortunately, at the moment, we don't have any job vacancies.